declining incidence of large cell lung carcinoma in the united states effects of who reclassification in a seer analysis

Original title: “Declining Incidence of Large Cell Lung Carcinoma in the United States: Effects of WHO Reclassification in a SEER Analysis.”

gastroparesis following anatomical resection for lung cancer clinical characteristics and implications

Original title: “Gastroparesis following anatomical resection for lung cancer: clinical characteristics and implications.”

As a result, targeted radionuclide ... of new treatment approaches, tailored to the nature and biology of different tumors. Later this year, a UK-based biotech company called Nuclide Therapeutics, is planning a clinical trial in lung cancer patients, a population with notoriously low overall survival rates. “The symptoms don’t often show until the disease has spread, ... As a result, targeted radionuclide therapy is set to become ever more varied and sophisticated in the coming years and could ultimately lead to a broad array of new treatment approaches, tailored to the nature and biology of different tumors. Later this year, a UK-based biotech company called Nuclide Therapeutics, is planning a clinical trial in lung cancer patients, a population with notoriously low overall survival rates. “The symptoms don’t often show until the disease has spread, making surgery difficult, and the cancer develops therapy resistance at a rapid rate,” says Tim Witney, professor of molecular imaging at King’s College London, and the company’s co-founder & CSO. Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating radionuclide therapies. After being approved by the FDA in early 2022, it has emerged as a novel life-extending option for patients with advanced disease. ... The success of this drug has resulted in PSMA becoming a focal point for other radionuclide therapies aimed at advanced prostate cancer. Bayer has two early-stage clinical trials in progress using PSMA to deliver higher energy radionuclides to patients with metastatic disease. But once there’s data that shows, ‘Ok, this is safe and also as effective as standard treatments,’ then radiopharmaceuticals could be moved up as a first-line option where it’s the patient’s and physician’s choice about which treatment they want to receive.” · I look forward to watching these clinical trials carefully over the coming years—and one day, hopefully, welcoming a new standard tool into our toolbox for treating cancer.

Original title: “Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers”

carcinomas and carcinoid tumors of the lungs and bronchi in children and adolescents the expert recommendations

Original title: “Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations.”

placental transmogrification of the lung misdiagnosed as cavitary lung cancer a case report

Original title: “[Placental transmogrification of the lung misdiagnosed as cavitary lung cancer: a case report].”

Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.

Original title: “Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program”

The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program.

Original title: “FDA Grants Second Approval under the National Priority Voucher Pilot Program”

Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid dividends.

Original title: “Boehringer drug approved in 44 days; BioMarin shelves Roctavian”

increase in second primary lung cancers in a nation wide cohort study from sweden

Original title: “Increase in second primary lung cancers in a nation-wide cohort study from Sweden.”

exploring the effects of tinzaparin and cisplatin on lung cancer cells in vitro

Original title: “Exploring the effects of tinzaparin and cisplatin on lung cancer cells in vitro.”

Sherlock-Lung study researchers use large-scale, multi-omics analysis to identify biomarker of aggressive lung tumors.

Original title: “NIH-led study reveals role of mobile DNA elements in lung cancer progression”

Forty percent of cancers diagnosed in the U.S. may have a link to tobacco use, according to this month's Vital Signs Report. Tobacco use is the leading preventable cause of cancer and cancer deaths. It causes more than lung cancer - based on current evidence, it can cause cancers of the mouth and throat, voice box, esophagus, stomach, kidney, pancreas, liver, bladder, cervix, colon and rectum, and a type of leukemia (acute myeloid leukemia).

Original title: “Cancers linked to tobacco use make up 40% of all cancers diagnosed in the United States - Press Release”

Puerto Rico has the lowest incidence rate of new lung cancer compared with all other races and ethnic groups in the United States, according to a study published today in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Original title: “Puerto Rico has lower rates of new cases of lung and breast cancer than the rest of US - Press Release”

We are deeply saddened by the passing of our friend Rosemary V. Hernandez, known to many as Rose. When smoking gave her lung cancer, she gave her story to millions, moving many to quit smoking or to never start.

Original title: “Statement from CDC Director Tom Frieden on the passing of Rosemary V. Hernandez, former Tips From Former Smokers ad participant - Media Statement”

Tobacco control efforts are having a major impact on Americans' health, a new analysis of lung-cancer data suggests. The rate of new lung cancer cases decreased among men and women in the United States from 2005 to 2009, according to a report in this week's Morbidity and Mortality Weekly Report.

Original title: “Rates of new lung cancer cases drop in U.S. men and women -Press Release”

The rates of new lung cancer cases in the United States dropped among men in 35 states and among women in 6 states between 1999 and 2008, according to a report by the Centers for Disease Control and Prevention.

Original title: “Lung cancer rates decline nationwide”

A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer...

Original title: “Annual Report to the Nation Finds Declines in Cancer Incidence and Death Rates; Special Feature Reveals Wide Variations in Lung Cancer Trends across States”